CellGebra
High failure rate of drug development projects due to lack of efficacy is strongly related to poor choice of drug targets and lack of patient selection in clinical trials. CellGebra’s solution is to predict cancer cell behaviour using digital copies of cell signalling networks. Digital copies of cell signalling networks can predict response to potential and existing drugs in different patients and identify new drug targets.
CellGebra has a melanoma digital twin under development. The digital twin will inform decision-making for progressing drug project at early stages, while help focus experimental efforts on most promising venues and increase number of successful projects in the pipeline.
Promoters
- Prof. Brona Murphy, Academic Founder
- Dr Katja Rybakova, Business Lead
Current status
- Completing EI Commercialisation Fund
- Seeking collaborative research opportunities with industry customers
Next steps
- Spin-out 2025
